Evidence review
Is injectable glutathione established for skin lightening, and what has the FDA said about it?
The answer
No trial supports it. Seven clinical trials pair glutathione with skin lightening and all seven were read: six test an oral, buccal, or topical preparation, and the seventh tests a four-ingredient injectable for under-eye pigment. The injected route returns no clinical trial at all.
Glutathione is a tripeptide of glutamate, cysteine, and glycine, and the body's most abundant intracellular antioxidant. It is synthesized in every cell rather than obtained mainly from outside, which is the first fact that sits awkwardly beside a market built on putting more of it into a vein.
The claim under test is narrow and specific: that injecting glutathione lightens skin. Proving it would take a controlled trial of the injected preparation, in people, with a pigment measure, against a comparator. That is a modest bar and it is the bar this review measures against. The monograph records the regulatory position with the date it was verified.
Searched in August 2026, the pairing of glutathione with skin lightening, whitening, bleaching, hyperpigmentation, or melanogenesis returns 206 indexed records, of which 98 carry the Humans subject heading, 7 carry the clinical-trial publication type, and 4 the stricter randomized-controlled-trial type [4].
All seven were read rather than counted, because seven is a number small enough to open and because a count of trials is not a finding about what was tested. Six test an oral, buccal, or topical preparation. An eight-week open-label single-arm study gave a glutathione lozenge daily to 30 Filipino women with Fitzpatrick skin types IV or V and reported a fall in melanin index detectable from two weeks, with no serious adverse events [1]. A double-blind randomized study in 46 participants compared combined topical and oral glutathione against each route alone, and found the combination produced a lower melanin index than placebo [2]. The remaining four test creams, a multi-plant powder, an oral cystine preparation, and a topical agent used with focused ultrasound [4].
The seventh is an injectable, and it is not a trial of this question. It randomized 120 patients with periorbital hyperpigmentation to injections of a sodium hyaluronate complex containing vitamin C, tranexamic acid, and glutathione [3]. Four active ingredients delivered under the eye for dark circles is a different product answering a different question from glutathione alone delivered into a vein for overall skin tone, and the trial cannot be read as evidence for the second.
Narrowing the same pairing to records that also name an intravenous, intramuscular, injection, or injectable route returns 12 indexed papers. Under the clinical-trial publication type it returns 0. Under the randomized-controlled-trial type it returns 0 [4].
That is the measurement this page exists to publish, and it is worth stating what stands behind it. A publication-type filter that has stopped matching returns zero for every substance in the database, so the same session ran a control term with a large and undisputed trial literature through the identical filter: 8,904 records under the clinical-trial type and 6,113 under the randomized type. The invalid tag that once produced a false zero on this site returned 0 for that same control term, and a deliberately invalid record identifier errored in the same run [4].
The zero is therefore a measurement rather than an assertion, and it is bounded by its own search string, which the reference below prints in full so the count can be repeated rather than trusted. What it says is that as of the date it was run, this index found no controlled trial of injected glutathione for skin lightening. It does not say no such study exists anywhere in any form; it says the indexed literature, searched this way, on this date, contains none.
One of the oral trials makes the same point from the inside. Its authors note that the highest plasma concentrations are achieved with intravenous administration but are accompanied by greater levels of risk, and that observation is precisely why they investigated a lozenge instead [1]. The route with the most exposure is the route with the least evidence.
The compounding position and the injectable skin-whitening trade are two different things, and only one of them is inside the pharmacy system. Glutathione is listed in Category 1 of the FDA's interim 503A bulks list, so licensed pharmacies may compound it against a valid prescription while the agency's review continues; the compoundable page records what that permits.
The trade in imported whitening injectables sits outside that entirely, and the federal record of it is dated. A consent decree of permanent injunction was entered in the United States District Court for the District of New Jersey on September 26, 2017 in United States v. Flawless Beauty LLC, a case the FDA still cites by case number in its own correspondence [5]. Under that decree the company announced on January 18, 2018 a recall of nineteen products, and the announcement the FDA republished states that all of the glutathione products were sold in multi-vial whitening kits, alone or with ampules of vitamin C and sterile water [6].
This index records that action as the dated public record it is and draws no conclusion from it about any other business. An enforcement action discloses conduct at one firm on one date. It is not a finding about a molecule, it is not a finding about an industry, and treating it as either would be the same error in the opposite direction from treating six oral trials as evidence for an injection.
Two questions get merged in this market and they have different answers. Does glutathione affect skin pigment? The oral and topical trials say something modest and short-term happens, and the systematic reviews that have looked at the field describe the evidence as limited and mixed. Does injecting it lighten skin? On the record searched here, nobody has run the trial.
The second answer is not a claim that the injection does nothing. It is a claim about what is known, which is the only claim this index makes. A reader weighing an infusion is weighing a route with no controlled evidence, a preparation whose contents are whatever the supplier states, and a documented history of enforcement in the import trade that supplies it.
The nearest comparison in this index is NAD+, which shares the Category 1 position and has the same distance between its precursor trials and its infusion. The approved peptides table sets out what a compound looks like when the trial actually was run.
Monographs
Reference tables
Every source below is inherited from a monograph in this index, where it was verified at writing time; this review introduces none of its own. The pointer beside each entry names the monograph and the reference number it came from.